SAN FRANCISCO — Despite all the hopeful chatter about the life sciences industry making a rebound after a multiyear ...

In his annual letter, Flagship Pioneering’s Noubar Afeyan lays out a choice between near-term “human-made miracles” and a ...

Noubar Afeyan, one of biotech’s top investors, says U.S. policy is "taking a sledgehammer to our miracle machine." ...

AI supercharges discovery; Nye and Afeyan warn U.S. anti-science cuts threaten health, competitiveness, future today.

In a new letter, Noubar Afeyan, Ph.D., co-founder of Moderna and CEO of Flagship Pioneering, warns that these actions risk undermining the foundations of science itself to the ultimate detriment of ...

The politicization of science is undermining the scientific method itself, the co-founder of the biotech firm Moderna warned.

According to reporting from Bloomberg at the J.P. Morgan Healthcare Conference that ended today in San Francisco, ...

AbbVie and Novartis strike billion-dollar pacts while attendees at the J.P. Morgan Healthcare Conference await that one big M ...

Former Federal Reserve chiefs, Republican senators and — perhaps most important, many bond investors — raised concerns about ...

In addition to Jefferies, Moderna also received a Hold from Morgan Stanley’s Terence Flynn in a report issued today. However, yesterday, Piper Sandler reiterated a Buy rating on Moderna (NASDAQ: MRNA) ...

Argus Research analyst Jasper Hellweg reiterated a Hold rating on Moderna yesterday. The company’s shares closed yesterday at $39.60. According to TipRanks, Hellweg is a 4-star analyst with an average ...

These days, an S&P 500 fund is less a diversified investment than a bet on whether AI will pay off for a handful of the world’s biggest companies.